Major Research Areas
Upstate boasts basic and clinical researchers with diverse expertise in neuroscience, molecular genetics, genomics, epigenetics, structural biology, infectious disease, and behavior disorders. This allows students the opportunity to perform research in a wide range of research areas and easily collaborate when new expertise is needed.
Dimitra Bourboulia, PhD
Research Programs and Affiliations
- Biomedical Sciences Program
Education & Fellowships
- Fellowship: National Cancer Institute, NIH, Bethesda, MD, 2013
- Fellowship: University of London, UK, 2007
- PhD: University of London, UK, 2004
- National Institutes of Health, 2007–2013
- University of London, UK, 1999–2007
- Extracellular kinase signaling
- Extracellular chaperone function
- Targeting extracellular signaling networks in urological cancers
- American Association for Cancer Research (AACR)
- American Urological Association (AUA)
Languages Spoken (Other Than English)
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Tumor cell growth and migration begin with the secretion of proteolytic enzymes that degrade the extracellular matrix (ECM) followed by an invasion of the tumor vasculature leading to initiation of metastasis. Matrix Metalloproteases (MMPs) and their endogenous inhibitors (TIMPs) are key components of extracellular proteolysis and regulators of the tumor microenvironment (TME). Identification of ways to inhibit early matrix proteolysis would enhance our ability to target early tumor development and prevent metastatic potential. Studies have suggested that MMP/TIMP balance is shifted towards MMP activation during cancer progression.
Our laboratory investigates molecular mechanisms of MMPs and TIMPs regulation in the extracellular space that impact homeostasis and cancer progression. Current areas of research includes: (1) How c-Src mediated tyrosine phosphorylation of TIMP-2 affects extracellular proteolysis, (2) The role of TIMP-2 as a regulator of extracellular protein homeostasis, (3) Targeting extracellular kinase signaling for the development of novel cancer therapies.